PA
ELV icon

PharVision Advisers’s Elevance Health ELV Stock Holding History

PharVision Advisers’s Portfolio ELV Stock Details ELV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-849
Closed -$369K – 309
2025
Q1 		$369K Buy
+849
New +$341K 0.51% 58

Other funds holding ELV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

PharVision Advisers's ELV Position: Q2 2025 in Review

PharVision Advisers sold out of Elevance Health (ELV) in Q2 2025, closing a stake of 849 shares — an estimated $369K sold.

PharVision Advisers first reported a position in ELV in Q1 2025 and held it in 1 quarter. The position peaked at $369K in Q1 2025. 1,589 funds tracked by Wall St. Rank hold ELV as of Q2 2025.

  • PharVision Advisers reported no remaining Elevance Health position as of Q2 2025 after selling out during the quarter.
  • PharVision Advisers sold 849 Elevance Health shares in Q2 2025, an estimated $369K.
  • PharVision Advisers first reported a position in Elevance Health in Q1 2025 and held it in 1 quarter.
  • PharVision Advisers's Elevance Health position peaked at $369K in Q1 2025.
  • 1,589 funds tracked by Wall St. Rank held Elevance Health as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.